Clinical Trial: Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX29 Compared With HLX11

U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07776132) titled 'Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX29 Compared With HLX11' on Aug. 17.

Brief Summary: This is a randomized, double-blind, parallel-controlled study to compare the PK profile of HLX29 and HLX11 and evaluate their safety, tolerability, and immunogenicity after a single intravenous dose in healthy male adult participants.

Study Start Date: Sept. 05

Study Type: INTERVENTIONAL

Condition: Health Adult Subjects

Intervention: DRUG: HLX29

Pertuzumab injection after process change

DRUG: HLX11

Pertuzumab injection before process change

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shanghai Henlius Bi...